•   
  •   
  •   

Politics FDA panel recommends booster shot of Johnson & Johnson vaccine

17:51  16 october  2021
17:51  16 october  2021 Source:   thehill.com

New FDA chief can't come soon enough for beleaguered agency

  New FDA chief can't come soon enough for beleaguered agency WASHINGTON (AP) — Straining under a pandemic workload and battered by a string of public controversies, one of the leading agencies in the government's fight against COVID-19 is finally on the verge of getting a new commissioner. After nearly nine months of searching, President Joe Biden says he’s close to naming his choice to lead the Food and Drug Administration, which oversees vaccines, drugs and tests. Former FDA officials and other experts say the decision cannot come soon enough for the agency's beleaguered regulators.

A Food and Drug Administration (FDA) advisory committee voted to recommend authorizing a second dose of Johnson & Johnson's COVID-19 vaccine.

a close up of a bottle: Johnson & Johnson vials © Getty Images Johnson & Johnson vials

The agency's vaccine advisory committee voted unanimously, 19-0, to recommend authorization of a second dose as early as two months after the primary shot for anyone ages 18 and older.

Johnson & Johnson representatives told the panel that a second dose given either two months or six months after the first shot increased antibody levels, but a single dose of the vaccine continued to offer protection.

The recommendation, which is not binding, will now be taken up by the FDA, which could make a decision within days.

Texas Tea Party gubernatorial candidate Allen West has pneumonia; infection rates falling - for now: Live COVID-19 updates

  Texas Tea Party gubernatorial candidate Allen West has pneumonia; infection rates falling - for now: Live COVID-19 updates Tea Party favorite and Texas gubernatorial candidate Allen West says he has tested positive for COVID-19 and probably will be hospitalized.West, 60, said he is not vaccinated and that his wife Angela West, who is vaccinated, also tested positive. Both have completed monoclonal antibody injections, West said on  Twitter. He also said he is "taking hydroxychloroquine and ivermectin protocols." Neither drug has received FDA approval for use against COVID.

Committee members expressed concern with the quality of data presented by the company, because there were ultimately only 17 people included in an analysis, who were followed for six months.

The FDA said it relied heavily on studies conducted by Johnson & Johnson and could not independently confirm many of the findings because data from the trials were not submitted in time.

Archana Chatterjee, an infectious disease expert at Rosalind Franklin University, asked FDA officials why there was even a meeting if the agency hadn't been able to conduct its own studies.


Video: FDA panel reviewing need for Johnson & Johnson COVID booster shots (CBS News)

Peter Marks, the head of the agency's vaccine division, said it could have taken months to review all the data, and the agency is trying to act as quickly as possible.

US to reopen land borders to vaccinated tourists; Florida county faces fine for vaccine requirement: COVID updates

  US to reopen land borders to vaccinated tourists; Florida county faces fine for vaccine requirement: COVID updates Starting next month, the United States will allow fully-vaccinated foreign nationals to cross its land borders for non-essential purposes.The change would allow foreign tourists to enter the U.S. through land or ferry ports for the first time since March 2020. Government officials have not yet announced a date for the policy change but said it will take place in "early November," in tandem with the country's updated international air travel system.

Still, the vote and subsequent FDA action will likely add some clarity to the path forward for the 15 million people who received a Johnson & Johnson vaccine.

The panel was originally asked to vote on a more complicated series of questions, including whether to recommend a booster six months after the initial dose. They asked to simplify the original questions instead, and voted on the two-month period.

Unlike the recommendations for boosters of Pfizer's and Moderna's vaccines, the panel did not limit who should get a booster. Many panel members said they always thought the vaccine would need a booster dose, and some wondered why it was presented as a single-dose shot.

Marks said it was used as an "outreach vaccine" to people who may not have been part of an organized health system. He also expressed some skepticism about the efficacy of a single dose, despite what the company was presenting.

Overnight Health Care — Presented by The National Council for Mental Wellbeing — FDA panel advises Moderna booster shot for high-risk people

  Overnight Health Care — Presented by The National Council for Mental Wellbeing — FDA panel advises Moderna booster shot for high-risk people Welcome to Thursday's Overnight Health Care, where we're following the latest moves on policy and news affecting your health. Subscribe here: thehill.com/newsletter-signup.What's the best way to get Moderna to share its vaccine with poor countries? According to Jimmy Kimmel, the U.S. should buy the formula, and then give it to McDonald's. "Sharing is caring!" An FDA advisory panel voted to recommend a booster dose of Moderna's COVID-19 vaccineWhat's the best way to get Moderna to share its vaccine with poor countries? According to Jimmy Kimmel, the U.S. should buy the formula, and then give it to McDonald's.

"All of the data don't align on this being a vaccine that retains strong efficacy over time against all forms of disease, including for more severe outcomes," Marks said. "There are data that suggest the effectiveness of their vaccine is less robust than what the company is presenting. That is a finding of concern."

Following the vote, the panel will discuss a study about the possibility of "mixing and matching" booster doses. A preliminary study from the National Institutes of Health found Johnson & Johnson vaccine recipients may benefit more from a booster of the Moderna or Pfizer-BioNTech vaccine.

The panel won't vote on a recommendation to authorize such a strategy, because the data is still considered preliminary, and the FDA has not yet reviewed the study.

Updated at 2:18 p.m.

FDA says Pfizer vaccine appears to work in young kids; study shows lower mortality rates for vaccinated people: Live COVID updates .
Pfizer’s COVID vaccine appears highly effective at preventing symptomatic infections in young kids and caused no unexpected safety issues, feds say.The Food and Drug Administration posted its analysis of Pfizer’s data ahead of a public meeting next week to debate whether the shots are ready for the nation’s roughly 28 million children ages 5 to 11. The agency will ask a panel of outside vaccine experts to vote on that question and is expected to authorize the vaccine for young children as early as next week.

usr: 1
This is interesting!